Clearbridge BioMedics' ClearCell® FX1 system achieves U.S. FDA listing

Monday, January 8, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

SINGAPORE, Jan. 8, 2018 /PRNewswire/ -- Clearbridge BioMedics today announced that it has successfully registered its

target cell enrichment device, the ClearCell® FX1 system, with the U.S. Food and Drug Administration (FDA) as a Class I Medical Device, for in vitro diagnostic use. This registration marks a significant milestone in providing a reliable liquid
biopsy solution for clinical research in the United States. The ClearCell® FX1 system has also previously attained CE marking to be used as an in-vitro diagnostic medical device in Europe and China Food and Drug Administration-approved Class I Medical Device status via the company's MGI partnership.

The ClearCell® FX1 System is a leading, automated, label-free liquid biopsy device for the enrichment of target cells from blood. The system incorporates the innovative microfluidics CTChip® to isolate and retrieve intact, viable target cells from a patient's blood sample.

Commercially launched in 2015, the ClearCell® FX1 System has since been installed in laboratories worldwide and empowered numerous liquid biopsy studies. In 2017, it was chosen to be part of the prestigious CANCER-ID consortium, where leading cancer institutes and researchers use the technology to better understand the underlying biology of circulating tumor cells (CTCs). The objective of such efforts is to generate new insights into the disease, to develop innovative cancer therapies and improve patient management protocols. The technology enables seamless processing of both CTCs and circulating tumor DNA (ctDNA) from the same patient sample for subsequent analysis, allowing comprehensive cancer profiling.

"We believe, the ClearCell® FX1 System will play a critical role in the development of new therapies by providing label-free, intact and viable cells for analysis. Successfully listing the unit with the U.S. FDA for in vitro diagnostic purposes will accelerate research and the adoption of diagnostics from the tumor cells obtained. We will continue to work with our partners and the authorities to further validate the system, for use in cancer diagnostics, personalized therapy management and patient monitoring," said Michael Paumen, CEO of Clearbridge BioMedics.

In the U.S. the ClearCell® FX1 system is sold directly through Clearbridge BioMedics Inc. In EMEA and Asia, the platform is currently available in more than 22 countries through distribution partnerships. In China, it is available through a strategic partnership with MGI, an associate of BGI.

About Clearbridge BioMedics

Clearbridge BioMedics Pte Ltd specializes in developing innovative systems with applications in oncology research and diagnostics. Clearbridge BioMedics has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX1 System. The ClearCell® FX1 system, when used in conjunction with its biochip and associated accessories, utilize state-of-the-art, non-invasive liquid biopsy to process blood samples for enrichment of CTCs. This enables the real-time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies. www.ClearbridgeBioMedics.com.

Cision View original content:http://www.prnewswire.com/news-releases/clearbridge-biomedics-clearcell-fx1-system-achieves-us-fda-listing-300578068.html

SOURCE Clearbridge BioMedics

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store